I got on them 3 yrs ago ish...bought for 3c �20K its going to be an amazing ride. I heard 3 yrs ago from an ex senior person of the actual company that she had been reliably informed that should the Diabicel and the NTCEL be successful a conservative SP estimate would be $20 soon after commercialisation. Well we are not far off commercialisation already. She also told me that at least 3 major governments where keeping a close eye on developments with a view to massive financial support should things progress well. The savings that a government could make by adopting these treatments are phenomenal.... Thanks for the tip on Hotcopper blog btw Very helpfull....Looking fwd to the imminent newsletter they are talking about.....See you in Monti Carlo in a couple of years ...Ill be the guy in the white Panama hat drinking crystal in the supersized Sunseaker
Hardman &co valuation ► Valuation: The market is expected to re-rate the shares once full pain relief statistical analysis is published. FUM is still forecast to reach break-even and become cashflow positive in 2018. Our risk-adjusted DCF remains at 126p per share. Any licensing deal would provide further upside potential.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.